A Phase I/Ib Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy and in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors

Trial Profile

A Phase I/Ib Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy and in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs SAR 408701 (Primary) ; Dexamethasone; Diphenhydramine; Naphazoline; Tipiracil/trifluridine
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top